Vir Biotechnology reported third quarter 2026 results with a net loss of $96.3 million, or $0.57 per share, compared with $163.1 million, or $1.17 per share, a year earlier. The prior-year period included a non-recurring $75.0 million milestone expense, and total revenues were a loss of $188 thousand versus $240 thousand of revenue in the prior year. The company also reported topline Phase 3 ECLIPSE 1 data for hepatitis delta expected in the fourth quarter of 2026, and said its cash runway extends into the second half of 2028.
Net loss was $96.3 million, or $0.57 per share, versus $163.1 million, or $1.17 per share, in Q3 2025
R&D expenses were $80.0 million versus $151.5 million a year earlier, which included a $75.0 million milestone expense
Cash, cash equivalents and investments were $901.3 million at September 30, 2026, down $106.5 million in the quarter
Topline ECLIPSE 1 Phase 3 data expected in Q4 2026; company expects cash to fund operations into the second half of 2028
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Vir Biotechnology, Inc.'s 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$68.56M
-7.6%
$-3.16
—
-638.9%
FY2024
$74.20M
-13.9%
$-3.83
—
-703.4%
FY2023
$86.18M
-94.7%
$-4.59
-219.8%
-713.7%
FY2022
$1.62B
+47.5%
$3.83
-3.3%
31.9%
FY2021
$1.10B
+1334.4%
$3.96
—
48.3%
Frequently asked questions
When is Vir Biotechnology's next earnings date?
Vir Biotechnology has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Vir Biotechnology earn last quarter?
For the quarter ended Sep 2026, Vir Biotechnology reported diluted EPS of $-0.57 on revenue of -$188.00K (-178.3%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.